search for




 

Updates of Radioiodine Treatment for Graves’ Disease
Int J Thyroidol
Published online November 15, 2019
© 2019 Korean Thyroid Association.

Shin Young Jeong

Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
Correspondence to:
Shin Young Jeong, MD, PhD, Department of Nuclear Medicine, Kyungpook National University Chilgok
Hospital, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea
Tel: 82-53-200-2852, Fax: 82-53-200-3419, E-mail: syjeong@knu.ac.kr
Received September 24, 2019; Revised October 18, 2019; Accepted October 27, 2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Radioiodine (RAI) has been used for the treatment of hyperthyroidism. RAI is administered orally as sodium
iodide (I-131) in solution or a capsule for the treatment of hyperthyroidism. RAI is rapidly incorporated into the
thyroid cells, and extensive local tissue damage occurs by beta emissions of I-131. The incidence rate of
hypothyroidism is 5-50% at the first year after RAI therapy and is positively associated with the dosage of RAI.
RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving
many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest
researches of the clinical questions about indications, optimal dose, efficacy, and side-effects.
Keywords :
Radioactive iodine, Graves’ disease, Thyroid, Hyperthyroidism


November 2019, 12 (2)